Joel W. Neal

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figure S2 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

  2026-06-17

• Supplementary Figure S1 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

  2026-06-17

• Supplementary Figure S3 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

  2026-06-17

• Supplementary Table S1 from Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

  2026-06-17

• Challenges in AI Based Tumor Board Case Summarization and RecommendationsPreprint

  Research Square · 2026-06-16

• Air pollution and the risk of second primary lung cancer among lung cancer survivors: the prospective UK Biobank cohort study

  British Journal of Cancer · 2026-04-27

• First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non–Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study

  Clinical Cancer Research · 2026-04-10 · 1 citations

• CODEX and H&E imaging data from cancer tissue microarrays and whole-slide sections

  Zenodo (CERN European Organization for Nuclear Research) · 2026-04-08

• A Multimodal Foundation Model of Spatial Transcriptomics and Histology for Biological Discovery and Clinical PredictionPreprint

  arXiv (Cornell University) · 2026-04-04 · 1 citations

• A Multimodal Foundation Model of Spatial Transcriptomics and Histology for Biological Discovery and Clinical Prediction

  arXiv (Cornell University) · 2026-04-04

• Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non–Small Cell Lung Cancer

  JCO Precision Oncology · 2026-04-01 · 1 citations

• Corrigendum to ‘Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System–Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes’ [JTO Clinical and Research Reports 6 (2025) 100914]

  JTO Clinical and Research Reports · 2026-03-20

• Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced <i>ALK</i> -Rearranged Squamous and Adenosquamous Non–Small Cell Lung Cancers

  JCO Precision Oncology · 2026-03-01

• KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status

  Cancer Treatment and Research Communications · 2026-01-01

• AI-enabled virtual spatial proteomics from histopathology for interpretable biomarker discovery in lung cancer

  Nature Medicine · 2026-01-01 · 25 citations

• Eligibility and Prognostic Performance of Smoking Duration–Based Versus Pack-Year–Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups

  Annals of Internal Medicine · 2025-12-15 · 1 citations

• Amivantamab Plus Lazertinib in Atypical <i>EGFR</i> -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2

  Journal of Clinical Oncology · 2025-12-01 · 2 citations

• Leveraging large language models to extract smoking history from clinical notes for lung cancer surveillance

  npj Digital Medicine · 2025-11-28 · 4 citations

• Supplemental Table 2 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials

  2025-11-26

• Supplemental Table 1 from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials

  2025-11-26